AIDS vaccine failures trigger 'Goldilocks' analogy

Despite its prevalence around the world and ongoing research, attempts to find an AIDS cure have been fruitless. Oregon Health & Science University (OHSU) researchers think the inability to find an effective AIDS vaccine may come down to not finding the right virus strain to make one. Dr. Louis Picker, associate director of the OHSU Vaccine and Gene Therapy Institute, describes the situation as analogous to, of all things, "Goldilocks and the Three Bears." "The field was looking for a vaccine that was 'not too hot,' or 'not too cold,' but 'just right,'" he said. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.